Digoxin toxicity and DigiFab

Overview

Digoxin has one of the narrowest therapeutic indices in clinical medicine. The gap between a therapeutic level and a lethal one is small, and toxicity is compounded by interactions that are ubiquitous in ICU patients, renal failure, electrolyte disturbances, polypharmacy. Understanding the pharmacology explains every clinical feature of toxicity, and DigiFab is among the most targeted antidotes in toxicology: knowing when and how to dose it is examinable and life-saving.

Pharmacology Relevant to Toxicity

Mechanism of Action

Digoxin inhibits the Na⁺/K⁺-ATPase pump on myocardial cell membranes. This pump normally extrudes 3 Na⁺ in exchange for 2 K⁺. Its inhibition causes:

• ↑ intracellular Na⁺ → saturates the Na⁺/Ca²⁺ exchanger (NCX) → ↑ intracellular Ca²⁺ → positive inotropy
• ↑ vagal tone via sensitisation of cardiac baroreceptors and direct vagomimetic effect → ↓ sinus rate, ↑ AV nodal refractoriness → negative chronotropy and dromotropy

At toxic concentrations, uncontrolled intracellular Ca²⁺ overload generates delayed afterdepolarisations (DADs) → triggered automaticity → ventricular ectopy, bidirectional VT, VF.

Key Pharmacokinetic Parameters

Pitfall: A digoxin level drawn <6 hours after an acute oral ingestion does not reflect tissue distribution, it will be falsely elevated. Repeat at 6 hours minimum.

Toxicity Mechanisms

Electrophysiological Consequences

The combination of increased automaticity (Ca²⁺ overload, DADs) and increased vagal tone (↑ AV block) creates a paradoxical situation: ectopic pacemakers fire while the AV node conducts poorly. This explains why almost any arrhythmia can occur in digoxin toxicity.

Classic arrhythmias:

• AV block (1st, 2nd, particularly Mobitz I/Wenckebach, 3rd degree)
• Paroxysmal atrial tachycardia with AV block ("PAT with block"), classically digoxin-toxic
• Bidirectional VT, alternating QRS axis beat-to-beat; pathognomonic of digoxin (or occasionally aconite) toxicity
• Junctional rhythms, accelerated junctional tachycardia common
• Sinus bradycardia / sinus arrest
• VT / VF, late, life-threatening, triggered by Ca²⁺ overload

The ECG in Digoxin Therapy vs Toxicity

Common Mistake: The "Salvador Dalí moustache" scooped ST depression is a marker of digoxin therapy (digitalis effect), not toxicity. Do not use it to diagnose or grade toxicity.

Hyperkalaemia in Acute Toxicity

Acute digoxin poisoning blocks Na⁺/K⁺-ATPase systemically → K⁺ cannot re-enter cells → hyperkalaemia.

This is a critical prognostic marker:

$$K^+ > 5.5 \, \text{mmol/L} \Rightarrow \text{mortality} \approx 50\% \text{ without antidote (historical data)}$$

• K⁺ >5.0-5.5 mmol/L in acute ingestion = indication for DigiFab (see below)
• Hyperkalaemia in chronic toxicity is less common, usually driven by renal failure
• Treat the K⁺ only by treating the toxicity (DigiFab); do not use calcium unless there is genuine cardiac arrest with no DigiFab available

Pitfall (CRITICAL): Avoid calcium for digoxin-induced hyperkalaemia. The theoretical concern is "stone heart", fixed hypercontracture of a Ca²⁺-overloaded myocardium causing refractory systole. Contemporary evidence weakens (but does not abolish) this concern. However, DigiFab is the definitive treatment; calcium risks delaying it and may worsen intracellular Ca²⁺ overload. If calcium is unavoidable (imminent cardiac arrest, no DigiFab), use it, but prioritise DigiFab.

Precipitants and Drug Interactions

Why Toxicity Occurs

Most ICU digoxin toxicity is chronic/cumulative rather than acute massive overdose. Common precipitants:

Pitfall: Amiodarone is the most clinically important interaction. Starting amiodarone in a digoxin-maintained patient without halving the digoxin dose is a common cause of iatrogenic toxicity.

Diagnosis and Risk Stratification

Clinical Features

Cardiac: Any arrhythmia (see above); haemodynamic instability in severe toxicity.

Non-cardiac (early warning signs, often precede arrhythmia):

• Nausea, vomiting, anorexia
• Visual disturbances, xanthopsia (yellow-green haloes), blurred vision
• Confusion, weakness, lethargy

Investigations

• Serum digoxin level, at ≥6 hours post-ingestion for acute; trough (pre-dose) for chronic monitoring
• 12-lead ECG, essential; serial monitoring
• Electrolytes (K⁺, Mg²⁺, Ca²⁺), direct prognostic and therapeutic relevance
• Renal function (eGFR/creatinine), determines ongoing clearance
• Thyroid function if chronic toxicity without obvious precipitant

Risk Stratification for Acute Ingestion

DigiFab (Digoxin-Specific Antibody Fragments)

Mechanism

DigiFab consists of Fab fragments of sheep-derived digoxin-specific antibodies. Each vial contains 40 mg of purified Fab fragments, which bind free digoxin with high affinity, rapidly removing it from Na/K-ATPase receptors. The digoxin-Fab complex is renally excreted (though this is slow; elimination still occurs by redistribution from tissues first).

• Each vial binds approximately 0.5 mg digoxin
• Onset of effect: within 30 minutes (often faster, visible arrhythmia resolution)
• After administration, total serum digoxin level rises (measures bound + free), free digoxin level is the only valid measure, but this is not routinely available; levels are unreliable for 5-7 days post-DigiFab

Indications for DigiFab

Acute ingestion, administer DigiFab if ANY of:

• Life-threatening arrhythmia (high-degree AV block, VT, VF, haemodynamic compromise)
• Ingestion >10 mg (adult) or >4 mg (child)
• Serum digoxin >15 ng/mL (at equilibrium, ≥6 hours post-ingestion)
• K⁺ >5.0-5.5 mmol/L in context of acute digoxin toxicity

Chronic toxicity, administer DigiFab if:

• Life-threatening arrhythmia
• K⁺ >6.0 mmol/L (more conservative threshold in chronic toxicity, where K⁺ elevation often reflects renal failure rather than pump blockade alone)
• Haemodynamic instability
• Significant end-organ dysfunction from toxicity

Special considerations:

• Yellow oleander and foxglove co-ingestion, cross-react with digoxin assay and respond to DigiFab; empiric dosing warranted
• Cardiac glycoside-containing plants (bufo toad venom, chansu, oleander), variable cross-reactivity; DigiFab often still effective

Dosing, DigiFab

Three approaches based on available clinical information:

1. Known serum level + weight (most precise):

$$\text{Vials} = \frac{\text{Digoxin level (ng/mL)} \times \text{Weight (kg)}}{100}$$

Example: Digoxin 4 ng/mL, 70 kg patient: $$= \frac{4 \times 70}{100} = 2.8 \Rightarrow \text{round up to 3 vials}$$

2. Known amount ingested:

$$\text{Vials} = \frac{\text{mg ingested} \times 0.8}{0.5}$$

Bioavailability correction 0.8 (oral); each vial binds 0.5 mg.

Example: 5 mg ingested: $$= \frac{5 \times 0.8}{0.5} = 8 \text{ vials}$$

3. Empiric dosing (unknown amount, life-threatening toxicity):

Administration

• Reconstitute each 40 mg vial in 4 mL sterile water → dilute in 100 mL sodium chloride 0.9%
• Administer over 30 minutes (bolus in cardiac arrest)
• Monitor for: anaphylaxis (rare, sheep protein; pre-treatment with antihistamine if time permits), hypomagnesaemia, hypokalaemia post-treatment (as K⁺ re-enters cells), worsening heart failure (loss of digoxin's inotropic support, significant in those dependent on it)

Post-DigiFab Monitoring

• Serum digoxin levels invalid for 5-7 days (assay detects total digoxin including Fab-bound)
• Rebound toxicity, possible as Fab-digoxin complexes are eliminated and tissue digoxin redistributes; monitor ECG for 12-24 hours (longer in renal failure)
• Electrolytes, K⁺ and Mg²⁺ may fall rapidly as pump function resumes; replace proactively
• Renal failure, Fab-digoxin complexes accumulate; prolonged monitoring for rebound

Management of Specific Complications

Bradycardia / AV Block

1. Atropine 0.6 mg IV (up to 3 mg total), first line, restores vagal blockade
2. Transvenous cardiac pacing, if atropine fails; pacing threshold may be elevated in digoxin toxicity, use higher outputs
3. DigiFab, definitive; if haemodynamically significant, administer concurrently with pacing

Pitfall: Isoprenaline can precipitate ventricular arrhythmias in digoxin toxicity, avoid or use with extreme caution.

Ventricular Tachyarrhythmias

• DigiFab first, most digoxin VT responds within 30 minutes
• Magnesium sulfate 2-4 g IV over 15-20 minutes, particularly for digoxin-induced torsades de pointes (can occur despite QT not being prolonged); also stabilises membranes
• Lidocaine, acceptable alternative for VT if DigiFab not immediately available (does not worsen AV conduction)
• Phenytoin, historical use for digoxin VT; rarely used now; can decrease AV block

Cardioversion paradox:

External cardioversion in digoxin toxicity carries risk of precipitating refractory VF. Reserve for haemodynamically unstable VT/VF only. Use the lowest effective energy, under sedation cover, after DigiFab administration if possible.

Hyperkalaemia

• Kayexalate / resonium, too slow; not appropriate acutely
• Haemodialysis, not effective for digoxin removal (large Vd) but may help K⁺ management
• Calcium, use only as last resort (see pitfall above); if used, can give calcium gluconate 10 mL 10% IV

Electrolyte Correction

• Hypokalaemia, replete aggressively (target K⁺ >4.0 mmol/L); hypokalaemia sensitises to digoxin toxicity and worsens arrhythmias
• Hypomagnesaemia, replete with magnesium sulfate; often co-exists with hypokalaemia and promotes digoxin toxicity
• Hypercalcaemia, treat underlying cause; avoid further calcium supplementation

Disposition and Adjuncts

Gastrointestinal Decontamination

• Activated charcoal (50 g single dose) within 1-2 hours of ingestion if airway protected and no bowel obstruction
• Multiple-dose activated charcoal (MDAC), interrupts enterohepatic circulation; reduces t½; consider in significant ingestion (50 g 4-hourly, 3-4 doses)
• Cholestyramine, historical; not routinely recommended

Dialysis and Haemoperfusion

• Not effective for digoxin removal due to large Vd (5-10 L/kg)
• Haemodialysis may be used to manage renal failure and electrolyte disturbances as adjuncts

Key Numbers Summary

ICU Relevance

Monitoring

• Continuous cardiac monitoring, for any suspected digoxin toxicity; arrhythmias can be sudden and fatal
• 12-lead ECG, serial; assess for evolving AV block, VT, bidirectional VT
• Electrolytes (K⁺, Mg²⁺, Ca²⁺), 4-hourly minimum in acute toxicity; post-DigiFab hypokalaemia is common and can trigger new arrhythmias
• Renal function, daily; drives clearance and rebound risk
• Digoxin levels, post-DigiFab, total digoxin levels are not interpretable; clinical endpoints guide management

Common ICU Scenarios

1. Chronic digoxin toxicity with AKI, most common ICU presentation; renal failure causes accumulation; treat precipitant, hold digoxin, low-dose DigiFab for arrhythmia
2. Amiodarone-digoxin interaction, patient admitted for AF management started on amiodarone, develops complete heart block on digoxin; DigiFab + pacing
3. Acute overdose, intentional or accidental; large Vd means dialysis unhelpful; DigiFab, MDAC, supportive care
4. Plant-related cardiac glycoside poisoning, yellow oleander is relevant in South/Southeast Asian patient populations presenting to Australian hospitals; cross-reacts with digoxin assay; DigiFab indicated empirically

Escalation Triggers

• Haemodynamic instability → DigiFab + transvenous pacing team
• K⁺ >5.0 mmol/L rising → DigiFab now; contact pharmacy for vials
• Bidirectional VT → DigiFab bolus; avoid cardioversion until DigiFab given
• Rebound arrhythmia post-DigiFab → repeat dose; prolonged monitoring in renal failure

Pitfalls Summary

1. Don't give calcium for digoxin-toxic hyperkalaemia, give DigiFab.
2. Don't cardiovert until DigiFab is on board, precipitates refractory VF.
3. Don't trust digoxin levels for 5-7 days post-DigiFab, clinical endpoints only.
4. Don't forget amiodarone halves the digoxin dose requirement, failure to adjust causes toxicity.
5. Don't draw levels <6 hours post-ingestion, unreliable pre-equilibration.
6. Do replete K⁺ and Mg²⁺ aggressively, both sensitise to digoxin toxicity and worsen arrhythmias.
7. Do monitor for hypokalaemia post-DigiFab, as pump function restores, K⁺ re-enters cells rapidly.